Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

NCT06154902 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Idecabtagene vicleucel
OTHER: Not treated

Sponsor

Bristol-Myers Squibb